OpenURL Connection Search

Select item for more details and to access through your institution.

Noninvasive Monitoring of Mantle Cell Lymphoma by Immunoglobulin Gene Next-Generation Sequencing in a Phase 2 Study of Sequential Chemoradioimmunotherapy Followed by Autologous Stem-Cell Rescue.
Published in:
2021
By:
- Kumar, Anita;
- Bantilan, K.S.;
- Jacob, A.P.;
- Park, A.;
- Schoninger, S.F.;
- Sauter, C.;
- Ulaner, G.A.;
- Casulo, C.;
- Faham, M.;
- Kong, K.A.;
- Grewal, R.K.;
- Gerecitano, J.;
- Hamilton, A.;
- Hamlin, P.;
- Matasar, M.;
- Moskowitz, C.H.;
- Noy, A.;
- Palomba, M.L.;
- Portlock, C.S.;
- Younes, A.
Publication type:
journal article
MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 122, doi. 10.1002/hon.3163_83
By:
- Sehn, L. H.;
- Bartlett, N. L.;
- Matasar, M.;
- Schuster, S. J.;
- Assouline, S.;
- Giri, P.;
- Kuruvilla, J.;
- Shadman, M.;
- Cheah, C. Y.;
- Fay, K.;
- Ku, M.;
- Nastoupil, L.;
- Wei, M. C.;
- Yin, S.;
- To, I.;
- Hu, N.;
- Min, J.;
- Penuel, E.;
- Belousov, A.;
- Coimbra, A.
Publication type:
Article
Cause of death and prognosis of patients (pts) with primary refractory disease, and prognosis of pts reaching PFS24: Descriptive analysis of POLARIX.
Published in:
Hematological Oncology, 2023, v. 41, p. 432, doi. 10.1002/hon.3164_318
By:
- Herbaux, C.;
- Dietrich, S.;
- McMillan, A.;
- Thieblemont, C.;
- Gonzalez‐Barca, E.;
- Pinto, A.;
- Fogliatto, L.;
- Matasar, M.;
- Lee, C.;
- Hernandez, J.;
- Hirata, J.;
- Ho, R.;
- Launonen, A.;
- Boissard, F.
Publication type:
Article
Outcomes in primary gastrointestinal (GI) follicular lymphoma (FL): results from a multicenter analysis.
Published in:
Hematological Oncology, 2023, v. 41, p. 380, doi. 10.1002/hon.3164_275
By:
- St‐Pierre, F.;
- Alrifai, T.;
- Alhamad, K.;
- McCall, B.;
- Annunzio, K.;
- Mi, X.;
- Doukas, P. G.;
- Schoen, A.;
- Fu, L.;
- Au, C.;
- Otto, N.;
- Rojek, A.;
- Kline, J.;
- Cohen, J. B.;
- Matasar, M. J.;
- Epperla, N.;
- Ollila, T. A.;
- Fitzgerald, L.;
- Danilov, A. V.;
- Shouse, G.
Publication type:
Article
PHASE I STUDY OF BENDAMUSTINE, RITUXIMAB, IBRUTINIB, AND VENETOCLAX IN RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.88_2881
By:
- Kumar, A.;
- Batlevi, C.;
- Drullinsky, P.;
- Grieve, C.;
- Laraque, L.;
- Joseph, A.;
- Mahajan, N.;
- Matasar, M.;
- Straus, D.;
- Zelenetz, A.;
- Hamlin, P.
Publication type:
Article
PRELIMINARY ACTIVITY OF DEVIMISTAT (CPI 613) IN PATIENTS WITH RELAPSED OR REFRACTORY BURKITT LYMPHOMA/LEUKEMIA.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.84_2881
By:
- Nikolaenko, L.;
- Pardee, T. S.;
- Steiner, R.;
- Abramson, J. S.;
- Horwitz, S.;
- Matasar, M.;
- Owens, C.;
- Rodriguez‐Rivera, I.;
- Straus, D.;
- Luther, S.;
- Noy, A.
Publication type:
Article
PROGNOSTIC SIGNIFICANCE OF TIME FROM LAST THERAPY IN PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA: RETROSPECTIVE ANALYSIS OF ELECTRONIC HEALTH RECORDS AND CLAIMS DATA IN THE US.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.80_2880
By:
- Matasar, M.;
- Castro, F.;
- Liu, Y.;
- Abraham, A.;
- Oki, Y.;
- Dickinson, M.
Publication type:
Article
CLINICAL OUTCOMES AND THE ROLE OF OBSERVATION IN EARLY‐STAGE FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.32_2880
By:
- Sha, F.;
- Okwali, M.;
- Alperovich, A.;
- Caron, P. C.;
- Falchi, L.;
- Hamilton, A.;
- Hamlin, P. A.;
- Horwitz, S. M.;
- Joffe, E.;
- Kumar, A.;
- Matasar, M. J.;
- Moskowitz, A. J.;
- Noy, A.;
- Owens, C.;
- Palomba, L. M.;
- Rodriguez‐Rivera, I.;
- Straus, D.;
- von Keudell, G.;
- Zelenetz, A. D.;
- Yahalom, J.
Publication type:
Article
CARDIOTOXICITY RISK IN PATIENTS WITH NON‐HODGKIN LYMPHOMA RECEIVING EPOCH AFTER PRIOR ANTHRACYCLINE EXPOSURE.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.193_2880
By:
- Buege, M. J.;
- Dao, P. H.;
- Drill, E.;
- Horwitz, S. M.;
- LeVoir, A.;
- Pak, T.;
- Peterson, T. J.;
- Matasar, M. J.
Publication type:
Article
ESCALADE: A PHASE 3 STUDY OF ACALABRUTINIB IN COMBINATION WITH R‐CHOP FOR PATIENTS ≤65Y WITH UNTREATED NON‐GERMINAL CENTER B‐CELL–LIKE DIFFUSE LARGE B‐CELL LYMPHOMA.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.164_2880
By:
- Sehn, L. H.;
- Kahl, B.;
- Matasar, M.;
- Lentz, G.;
- Izutsu, K.;
- Zhao, W.;
- Tao, L.;
- Calvo, R.;
- Zinzani, P. L.
Publication type:
Article
CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB‐ERA.
Published in:
Hematological Oncology, 2019, v. 37, p. 251, doi. 10.1002/hon.60_2630
By:
- Bobillo, S.;
- Joffe, E.;
- Lavery, J.;
- Noy, A.;
- Palomba, L.;
- Straus, D.J.;
- Kumar, A.;
- Batlevi, C.;
- Horwitz, S.;
- Moskowitz, A.;
- Hamlin, P.;
- Zelenetz, A.;
- Matasar, M.;
- Keudell, G.;
- Sermer, D.;
- Yahalom, J.;
- Dogan, A.;
- Seshan, V.;
- Younes, A.
Publication type:
Article
AN ONGOING PHASE 1/1B TRIAL INVESTIGATING NOVEL TREATMENT REGIMENS WITH MOSUNETUZUMAB IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 567, doi. 10.1002/hon.15_2632
By:
- Kim, W.S.;
- Assouline, S.;
- Bartlett, N.L.;
- Bosch, F.;
- Budde, L.E.;
- Cheah, C.;
- Gregory, G.P.;
- Hong, J.;
- Ku, M.;
- Marlton, P.;
- Matasar, M.;
- Nastoupil, L.;
- Panizo, C.;
- Sehn, L.H.;
- Tzachanis, D.;
- Chu, W.;
- Hernandez, M.G.;
- Kwan, A.;
- Li, C.C.;
- Sison, I.
Publication type:
Article
SAFETY AND EARLY DATA FROM A PHASE II TRIAL OF PEMBROLIZUMAB (PEM) AND ENTINOSTAT (ENT) IN RELAPSED AND REFRACTORY (R/R) HODGKIN LYMPHOMA (HL) AND FOLLICULAR LYMPHOMA (FL).
Published in:
Hematological Oncology, 2019, v. 37, p. 331, doi. 10.1002/hon.143_2630
By:
- Sermer, D.;
- Vardhana, S.;
- Batlevi, C.;
- Hamilton, A.;
- Moskowitz, A.;
- Caron, P.;
- Moskowitz, C.;
- Matasar, M.;
- Biggar, E.;
- Leung, E.;
- Yahalom, J.;
- Rademaker, J.;
- Dogan, A.;
- Seshan, V.;
- Younes, A.
Publication type:
Article
MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL).
Published in:
Hematological Oncology, 2019, v. 37, p. 310, doi. 10.1002/hon.119_2630
By:
- Sehn, L.H.;
- Assouline, S.;
- Bartlett, N.L.;
- Bosch, F.;
- Diefenbach, C.M.;
- Flinn, I.;
- Hong, J.Y.;
- Kim, W.S.;
- Matasar, M.;
- Nastoupil, L.;
- Schuster, S.J.;
- Shadman, M.;
- Yoon, S.S.;
- Bender, B.;
- Chu, W.;
- Hernandez, G.M.;
- Kwan, A.;
- McCall, B.;
- Sison, I.;
- Wang, C.
Publication type:
Article
IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 152, doi. 10.1002/hon.109_2629
By:
- Batlevi, C.L.;
- Sha, F.;
- Alperovich, A.;
- Ni, A.;
- Smith, K.;
- Ying, Z.;
- Hamlin, P.;
- Horwitz, S.M.;
- Kumar, A.;
- Matasar, M.;
- Moskowitz, A.J.;
- Moskowitz, C.H.;
- Noy, A.;
- Palomba, M.L.;
- Portlock, C.;
- Straus, D.;
- Boccomini, C.;
- Tucci, A.;
- Zelenetz, A.D.;
- Seshan, V.E.
Publication type:
Article
CLINICAL CHARACTERISTICS AND OUTCOMES OF STAGE I DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) IN THE RITUXIMAB‐ERA.
Published in:
Hematological Oncology, 2019, v. 37, p. 251, doi. 10.1002/hon.60_2630
By:
- Bobillo, S.;
- Joffe, E.;
- Lavery, J.;
- Noy, A.;
- Palomba, L.;
- Straus, D.J.;
- Kumar, A.;
- Batlevi, C.;
- Horwitz, S.;
- Moskowitz, A.;
- Hamlin, P.;
- Zelenetz, A.;
- Matasar, M.;
- Keudell, G.;
- Sermer, D.;
- Yahalom, J.;
- Dogan, A.;
- Seshan, V.;
- Younes, A.
Publication type:
Article
AN ONGOING PHASE 1/1B TRIAL INVESTIGATING NOVEL TREATMENT REGIMENS WITH MOSUNETUZUMAB IN RELAPSED/REFRACTORY B‐CELL NON‐HODGKIN LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 567, doi. 10.1002/hon.15_2632
By:
- Kim, W.S.;
- Assouline, S.;
- Bartlett, N.L.;
- Bosch, F.;
- Budde, L.E.;
- Cheah, C.;
- Gregory, G.P.;
- Hong, J.;
- Ku, M.;
- Marlton, P.;
- Matasar, M.;
- Nastoupil, L.;
- Panizo, C.;
- Sehn, L.H.;
- Tzachanis, D.;
- Chu, W.;
- Hernandez, M.G.;
- Kwan, A.;
- Li, C.C.;
- Sison, I.
Publication type:
Article
SAFETY AND EARLY DATA FROM A PHASE II TRIAL OF PEMBROLIZUMAB (PEM) AND ENTINOSTAT (ENT) IN RELAPSED AND REFRACTORY (R/R) HODGKIN LYMPHOMA (HL) AND FOLLICULAR LYMPHOMA (FL).
Published in:
Hematological Oncology, 2019, v. 37, p. 331, doi. 10.1002/hon.143_2630
By:
- Sermer, D.;
- Vardhana, S.;
- Batlevi, C.;
- Hamilton, A.;
- Moskowitz, A.;
- Caron, P.;
- Moskowitz, C.;
- Matasar, M.;
- Biggar, E.;
- Leung, E.;
- Yahalom, J.;
- Rademaker, J.;
- Dogan, A.;
- Seshan, V.;
- Younes, A.
Publication type:
Article
MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL).
Published in:
Hematological Oncology, 2019, v. 37, p. 310, doi. 10.1002/hon.119_2630
By:
- Sehn, L.H.;
- Assouline, S.;
- Bartlett, N.L.;
- Bosch, F.;
- Diefenbach, C.M.;
- Flinn, I.;
- Hong, J.Y.;
- Kim, W.S.;
- Matasar, M.;
- Nastoupil, L.;
- Schuster, S.J.;
- Shadman, M.;
- Yoon, S.S.;
- Bender, B.;
- Chu, W.;
- Hernandez, G.M.;
- Kwan, A.;
- McCall, B.;
- Sison, I.;
- Wang, C.
Publication type:
Article
IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 152, doi. 10.1002/hon.109_2629
By:
- Batlevi, C.L.;
- Sha, F.;
- Alperovich, A.;
- Ni, A.;
- Smith, K.;
- Ying, Z.;
- Hamlin, P.;
- Horwitz, S.M.;
- Kumar, A.;
- Matasar, M.;
- Moskowitz, A.J.;
- Moskowitz, C.H.;
- Noy, A.;
- Palomba, M.L.;
- Portlock, C.;
- Straus, D.;
- Boccomini, C.;
- Tucci, A.;
- Zelenetz, A.D.;
- Seshan, V.E.
Publication type:
Article
A PHASE I TRIAL OF 19-28Z CAR-T CELLS POST-HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION (HDT-ASCT) FOR RELAPSED AND REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL).
Published in:
Hematological Oncology, 2017, v. 35, p. 138, doi. 10.1002/hon.2437_128
By:
- Sauter, C.;
- Riviere, I.;
- Senechal, B.;
- Ni, A.;
- Bernal, Y.;
- Wang, X.;
- Purdon, T.;
- Hall, M.;
- Moskowitz, C.;
- Giralt, S.;
- Matasar, M.;
- Curran, K.;
- Park, J.;
- Sadelain, M.;
- Brentjens, R.
Publication type:
Article
BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET-ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE.
Published in:
Hematological Oncology, 2017, v. 35, p. 36, doi. 10.1002/hon.2437_17
By:
- Moskowitz, A.J.;
- Schöder, H.;
- Gavane, S.;
- Thoren, K.L.;
- Fleisher, M.;
- Yahalom, J.;
- McCall, S.J.;
- Fox, S.Y.;
- Gerecitano, J.;
- Grewal, R.;
- Hamlin, P.A.;
- Horwitz, S.;
- Kumar, A.;
- Matasar, M.;
- Ni, A.;
- Noy, A.;
- Palomba, M.L.;
- Perales, M.;
- Portlock, C.S.;
- Sauter, C.
Publication type:
Article
POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FL OR DLBCL: UPDATED RESULTS OF A PHASE 1B/2 STUDY.
Published in:
Hematological Oncology, 2017, v. 35, p. 271, doi. 10.1002/hon.2438_144
By:
- Matasar, M.;
- Herrera, A.F.;
- Kamdar, M.;
- Mehta, A.;
- Assouline, S.;
- Fleury, I.;
- Kim, T.M.;
- Kim, W.S.;
- Bosch, F.;
- Radford, J.;
- Flowers, C.R.;
- Bu, L.;
- Hong, W.;
- Sehn, L.H.
Publication type:
Article
PHASE I/IB DOSE ESCALATION AND EXPANSION OF IBRUTINIB AND BUPARLISIB IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, MANTLE CELL LYMPHOMA, AND FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2017, v. 35, p. 54, doi. 10.1002/hon.2437_38
By:
- Batlevi, C.;
- Hamlin, P.;
- Matasar, M.;
- Gerecitano, J.;
- Drullinsky, P.;
- Hamilton, A.;
- Straus, D.;
- Horwitz, S.;
- Kumar, A.;
- Moskowitz, C.;
- Moskowitz, A.;
- Zelenetz, A.;
- Ahsanuddin, S.;
- Callan, D.;
- Freidin, B.;
- Porzio, R.;
- Soiffer, J.;
- Copeland, A.;
- Dang, T.;
- Rademaker, J.
Publication type:
Article
Whole-body diffusion-weighted MR imaging in lymphoma surveillance.
Published in:
Hematological Oncology, 2017, v. 35, p. 304, doi. 10.1002/hon.2439_39
By:
- Rademaker, J.;
- Ryan, D.;
- Matasar, M.;
- Portlock, C.
Publication type:
Article
DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF THERAPY AND IMPACT OF DYNAMIC CHANGES IN FLIPI FOR MULTIPLY RELAPSED FOLLICULAR LYMPHOMA IN THE RITUXIMAB ERA.
Published in:
Hematological Oncology, 2017, v. 35, p. 229, doi. 10.1002/hon.2438_92
By:
- Batlevi, C.;
- Alperovich, A.;
- Ni, A.;
- Soumerai, J.;
- Smith, K.;
- Ying, Z.;
- Caron, P.;
- Drullinsky, P.;
- Gerecitano, J.;
- Hamilton, A.;
- Hamlin, P.;
- Horwitz, S.;
- Kumar, A.;
- Matasar, M.;
- Moskowitz, A.;
- Moskowitz, C.;
- Noy, A.;
- Palomba, M.;
- Portlock, C.;
- Sauter, C.
Publication type:
Article

Found: 26